=====================RLLVF (Relevium TechnologiesCurrent Price: $0.0592Float: 122.64MWebsite | Recent News========================Legal Cannabis is Expected to Grow 230%, to $31.3 Billion in 2022Global spending on legal cannabis is expected to grow 230%, to $31.3 billion in 2022, compared to $9.5 billion in 2017, according to Arcview Market Research and BDS Analytics. The research suggests that most of that, nearly $23.4 billion, will be spent in the U.S. With more states voting for the legalization of marijuana and business interest sparking, that definitely makes sense.Marijuana Regulation: The FactsWhile Canada legalized marijuana in late 2018, it remains illegal under federal U.S. law and is still classified as a controlled substance without proven medical benefit, along with heroin and LSD. However, with some 30 states voting to make cannabis legal for medicinal use, recreational use, or both, marijuana regulation in the U.S. essentially is a hot mess.30 states have approved the legalization of marijuana for medical or recreational use or both.In 2018 alone, the following states voted in favor of marijuana legalization:Michigan: Voters legalized marijuana use and cultivation for people over the age of 21 and authorized the commercial sale of marijuana through state-licensed retailers.Missouri: Voters approved legalizing marijuana for medical purposes and allowing patients to cultivate plants at home.Oklahoma: Voters approved legalizing marijuana for medical use.Utah: Voters approved some use of marijuana for medical purposes.Who are the Top Players in this Sector at the MomentCanopy Growth Corp. (The first Canadian marijuana company, Canopy Growth Corp. is the world's largest publicly-traded weed company. The company owns and operates many brands, producing and marketing both medical and recreational strains. Tweed is one of the company's most popular brands, thanks to an association with rapper Snoop Dogg. For its 2019 fiscal year, it reported revenue of CAD 77.9 million or nearly $60 million.In October 2017,, the beverage giant, and maker of Corona beer bought a 9.9% stake in Canopy Growth. The deal offers both companies a chance at new product lines such as cannabis-infused beverages.Aurora Cannabis Inc. (Another big Canadian pot company, Aurora Cannabis became even bigger in March by acquiring rival MedReleaf in a $250 million all-stock deal that was touted as the world's largest marijuana deal to date. Consolidating operations will help the new entity cut costs and gain efficiency. According to a press release, Aurora and MedReleaf together expect to produce over 570,000 kilograms per year of cannabis through nine facilities in Canada and two in Denmark.Aurora debuted on the Canadianstock exchange (TSX) in October 2016 and trades in the U.S. on the NYSE.. (Nasdaq's first pot stock,is a Toronto-based cultivator of. In addition to Canada, Cronos serves international markets, shipping its products to Germany, building a facility in Israel, and starting a jointin Australia.does not have a presence in the U.S. due to the uncertainty in regulations.As of its 2018 fiscal year, the company generated $7.3 million in revenue.The Top Players Offer Little Upside PotentialOver the last 12 months, there has been tremendous hype on cannabis stocks. The widespread legalization in some states in the U.S. and all of Canada caused many stocks related to the pot industry to skyrocket, leaving little upside potential for investors late to the party.However, there are still some juicy opportunities out there...We've Found A Cannabis Stock That Still Has Plenty Of Room To RunThat company is Relevium Technologies, and it is publicly traded in three countries on three separate exchanges OTCQB: “RLLVF”, TSX.V: “RLV”, and Frankfurt: “6BX”.Relevium Technologies is hitting on all cylinders from both a business and technical perspective, and they recently released some market friendly news that is sure to grab the attention of Wall Street.The Company signed an exclusivity agreement to partner with SOS cannabis(“SOSCannabis”), which will provide pediatric customers with theto obtain free legal representation to seek reimbursement for the costs of medical cannabinoid therapy from different government agencies for the treatment of medical conditions for pediatric patients.The partnership agreement will provide Relevium’s pediatric customers with access to an experienced legal and case management team, who will prepare the case file and seek retroactive and prospective reimbursement for parents of pediatric patients at no cost. The agreement provides Relevium with a unique advantage in terms of its business development strategy and first to market positioning in terms of pediatric applications.Mr. Aurelio Useche,of Relevium stated: “As we prepare to enter the pediatric endo-medicinal market in Canada with an initial ten (10) CannaKids® formulated products, not only are we providing parents with a natural alternative and/or health support mechanism, but now we are able to provide them with theto seek reimbursement from governmental agencies without any costs,” Mr. Useche stated further: “We are extremely happy to work with a team of caring legal professionals that can represent our customers in minimizing the financial burden of cannabinoid therapy.”Maitre Robert Astell, President of SOSCannabis.com stated “We are delighted to welcome Relevium into our family of medicinal cannabinoid therapy suppliers. The focus andof Relevium in terms of pediatric patients is admirable and we look forward to onboarding parents into our fully-automated registration platform and to provide them with the state-of-the-art case management service in fulfilling their need for economic assistance in providing natural medicine to their children.”Tracy Ryan,of Cannakids® stated: “For years patients have struggled with the high expenses that come along with using cannabis as a medicine. Especially parents to sick children who often lose their jobs due to countless hospital stays and doctor’s appointments. This new opportunity for families is a major step in the right direction. We are elated that more will now have the opportunity to afford this powerful, non-toxic option that we have seen bring unimaginable relief to patients on a global scale.”About Relevium TechnologiesRelevium Technologies operates in the health andindustry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the health andmarkets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health andconsumer products.Relevium’s products are part of the $3.72 trillion dollar globalindustry — one of the fastest growing worldwide markets. Their specific focus is on products that promote overall health, nutraceuticals, fitness nutrition and cosmeceuticals. The company already has 25 products being sold on Amazon with more being planned.Relevium operates through two wholly owned subsidiaries:BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including such as Walmart.com and Amazon.com.The company’s product offering includes cutting-edge line of weight-loss, anti-inflammatory, heart, vision, beauty and fitness supplements sold through their Bioganix®, Push & Pull System® and LeefyLyfe® brands with the objective of helping people lose weight, become healthier, happier, and most importantly achieve the results that our customers desire.Bioganix®, founded in 2014, has some of the best-selling products in the Health and Personal Care category on Amazon, and a loyal customer base. The combination of online marketing with an emphasis on superior quality products backed by stringent scientific research and formulations, this has developed Bioganix® in becoming one of the leading dietary supplement brands online.Push & Pull®, launched in 2019, is the first comprehensive natural anti-aging system for complete skin care that combines Collagen Protein supplements (PUSH) and naturally sourced Aloe Vera skin anti-aging cream (PULL). This new brand targets a brand-new revenue stream in the burgeoning cosmeceutical market, which is the fastest growing segment of the health andMarket.LeefyLyfe® is their OTC cannabidiol Phyto formulated brand that combines the same trusted ingredients as those found in Bioganix® and Push & Pull® with the benefits of. The company is currently waiting for the decision by the FDA to allow the sale ofas a supplement in order to release its products into the market.Since 2017, Relevium’s OTC has grown its product offering and expanded its distribution channels to some of the largest online marketplaces such as, Amazon and Walmart.com. Relevium will continue to innovate with the BioGanix brand, expand the product line and distribution channels to further drive growth.Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.The company combines leading biopharma expertise, agricultural and logistic advantages of Colombia and trusted brand status with a clinically validation process for Phyto therapeutic medical products aimed at pediatric applications.Biocannabix’ vertically integrated operations are located in key markets around the world: Canada, Colombia and Germany.Scientific and Administrative Offices located in Montreal, QuebecCultivation and Extraction operations with an initial 20 hectares located in, ColombiaDistribution and compliance partnership in GermanyThe portfolio of Biocannabix brands include:Cannakids®: Pediatric brand exclusive for the Canadian marketRelevium Senior®: Geriatric brand targeting inflammatory conditions including joints, heart and brain.Relevium Kids®: Pediatric brand of Nutraceuticals and Oral Nutritional SupplementsInvestment Highlights:In 2017, the globalmarket reached $4.2T.Global nutraceutical market to reach US$578.23B by 2025.Vast distribution network through industry giants like Walmart and Amazon.Building out 93,000-square-foot "Green Wave" cultivation and processing facility in Montreal, Quebec.BioGanix generates approximately $1M in revenue per quarter.47 SKUs developed for BioGanix to date.Acquiring Cannakids’s, a leader in medical "Green Wave" patient research and pediatric and adult consumer product development.Pending Sleipnir acquisition will initially bring in US$500K to Relevium’s topline revenue.Partnership in place with HempCo Canada.International expansion plans for all brands.Relevium In the NewsRelevium’s Biocannabix Positions Itself as an Important Player in Colombia as it Pursues Endo-Medical Cannabis Strategy for Latin AmericaEarlier this month, RLVRelevium’s Biocannabix positioned itself as an important player in the Colombian medical cannabis market by cementing medical and research relationships in the country in order to establish clinical validation programs for itsNutraceutical Supplements (ENS) and Oral Nutritional Supplements.On June 13th, 2019, the Company announced a binding LOI to acquire LifeLine, a binding agreement to acquire the shares of Lifeline, abased cultivation and extraction business in the burgeoning agro-pharma market in Colombia. With a much lower cost of production, a robust commercial and legal framework and a culture that is open to Phyto therapeutic medicine, Colombia is quickly becoming a global center of medical cannabis supply and it is forecasted that the Country will be looking to supply as much as 44% of the World’s demand.“This is a major strategic step in the development of our Phyto therapeutic biopharma business” stated Aurelio Useche,of Relevium Technologies.The Company’s subsidiary, Biocannabix Health Corporation, is a vertically integrated medical cannabis company with strategic positioning in three major markets: Canada, Latin America and Europe.The company’s operations in Montreal allows Biocannabix to leverage leading edge scientific and research platforms as well as government incentives in the province of Quebec. The recent acquisition of LifeLine in Colombia allows the company to leverage lower costs of cultivation and processing as well as to manage its own genetics for the production of targeted Phyto therapeutic formulations. Colombia, Canada and Germany combined are central to the clinical validation program for the ENS and ONS products that will be offered in all three markets.Relevium Takes Major Step in Latam to Acquire Lifelinein, ColombiaBiocannabix Health Corporation (“Biocannabix”), a wholly-owned subsidiary of Relevium has executed on June 12, 2019 a binding agreement to acquire the shares of Lifeline, abased cultivation and extraction business in the burgeoningmarket in Colombia.KEY HIGHLIGHTS OF THE PARTNERSHIP WITH LIFELINEBest in class partnership for international vertical integration.Combination of Biocannabix focus on Pediatric Endo-Medicine with a large-scale operation with 150 years of sustainable, environmentally responsible and organic agricultural historyLocated in Rozo, Valle del Cauca, in the heart of thecane enclave seven minutes away from the international airport and 10 minutes away from Cali’s downtown core and a population of overpeopleMulti-stage project with (1) an initial 5 hectares that includes the local offices, a laboratory, a fully enclosed greenhouse for tissue culture and micropropagation and an initial cultivation of over 200,000 square feet in open air green houses, (2) an option to expand to an additional 20 hectares or 2.2 million square feet of open air greenhouse cultivation and (3) the possibility to expand to another additional 60 hectares or 6.5 million square feet of cultivation.Full registration of 668 genetic strains with the, the Instituto Colombiano Agropecuario.Three licenses in progress including (1) extraction and manufacturing, (2) cultivation withand (3) non-psychoactive cultivation, all with scientific research, domestic sales and export modalities.Strategic low-cost infrastructure that allows for an estimated stage two flower capacity of 170,000per year with an initial estimated cost of production 0.53$ per gram.Development of an industrial scale extraction plant in the Pacific Free Zone, a private industrial park located minutes away from the cultivation project. The free zone offers the benefits of the free regime and seeks to promote and develop the process of industrialization of goods, the productive chain and the provision of services, as well as strengthen the competitiveness of its users and customers by taking advantage of the generated opportunities from international trade and bilateral agreements signed by Colombia.Genetics laboratory and agronomic research in the BioParque del Pacifico located in the campus of the International Center for Tropical Agriculture (CIAT) and the Colombian Corporation for agricultural research (Agrosavia).STRATEGIC FIT FOR GLOBAL SUPPLY AND VERTICAL INTEGRATIONRelevium’s Bio-Pharma arm, Biocannabix, is focused in developing, marketing and selling endo-medicinal formulations on Nutraceuticals and Medicalaimed primarily to pediatrics. An essential component of the strategy of delivering safe, 100% auditable medicine for pediatric patients is to ensure total control over the genetics, the cultivation and the processing of extracts. The partnership with Lifeline ensures a 100% organically grown product with access to over 600 registered genetic strains, the buildout of an EU GMP extraction facility in the Pacific Free Zone and theto trace and fully audit the process from seed to medicine through blockchain technology.The strict regulation of the Colombian legal regime for cannabis only allow for the export of extracts and finished goods and we aim to service international demand for organically sourced medical cannabis extracts for LATAM, Europe and eventually the Asian continent.LOCAL MARKET THAT IS READY TO ADOPT ENDO-MEDICINAL FORMULATIONSTraditional remedies and natural medicine are an integral part of Colombian culture and with a fast-growing middle class and entrepreneurial nature, this market with a population of over 49 million is moving quickly to adopt cannabinoid therapy. Lifeline, through Biocannabix pediatric formulations, is poised to successfully obtain a significant market share of the local market.TRANSACTION DETAILSUnder the terms of the binding agreement, Biocannabix will acquire 100% of the shares on Lifelineby investing an initial US$850,000 to be deployed during stage one of the projects. The initial investment is comprised of US$125,000 at signing, US$125,000 upon the grant of the initial licenses and a commitment to deploy funds totalling US$600,000 over the next seven months. As part of the transaction, Biocannabix Health Corporation will issue US$3,650,000 in shares representing approximately 41% of the shares outstanding of the wholly owned subsidiary.In the event of a major transaction including a sale or a public offering, the shareholders of Lifelinewill also receive an additional US$1.5 million to be settled in shares of Biocannabix or in cash.Aurelio Useche,of Relevium stated: “The acquisition and partnership with Lifelinein Colombia represents the single most important development to date for Relevium, our team and our shareholders. This is the culmination of months of strategic re-alignment, negotiations and a lot of hard work by our team and the key stakeholders of Lifeline”. Mr. Useche added:” We are very pleased and proud to partner with the amazing team of Lifeline, includingLIbrerosand Hossein Shadanlou COO and look forward to work together to execute on the common mission of providing safe, organically sourced and fully auditable endo-medicinal products for pediatric applications”LIbreros,of Lifelinestated: “With over 150 years of tradition in organic farming and our objective to provide the best medical cannabis extracts and products, we are happy (THRILLED) to join forces and merge with Biocannabix Health Corporation in Canada. We look forward to delivering real value through the disciplined deployment of our operational strategy from Colombia to the world”Cannabis Cultivation and Extraction Potentially Costs 80% Less in Latin AmericaWith a much lower cost of production, a robust commercial and legal framework and a culture that is open to Phyto therapeutic medicine, Colombia is quickly becoming a global center of medical cannabis supply and it is forecasted that the Country will be looking to supply as much as 44% of the World's demand.The region boasts exceptional climatic conditions, with lots ofand good rainfall. This coupled with acres and acres of arable land, could make the LATAM region the global leaders in cannabis production.In addition to the above, the price of labor is exceptionally cheap when compared to it's European and North American counterparts. Combined, it is estimated that LATAM will be able to produce cannabis – in commercial quantities – for nearly 80% less than the rest of the world. That's a pretty big advantage.The recent acquisition of LifeLine in Colombia allows the company to leverage lower costs of cultivation and processing as well as to manage its own genetics for the production of targeted Phyto therapeutic formulations. Colombia, Canada and Germany combined are central to the clinical validation program for the ENS and ONS products that will be offered in all three markets.The Bottom LineRLLVF deserves your immediate attentionWe suggest that you add this rapidly growing microcap cannabis company to the top of your watch-list, as these triggered technical indicators and company news could bring serious interest to this stock.Best Regards,DISCLAIMERThis newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negativeon share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated three thousand dollars by MJ Capital LLC for an investor relations advertising marketing campaign w/ 2000 TradingView™ views for RLLVF. Any compensation is a major conflict of interest in ourto be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.